Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

INO Investor Notice: Levi & Korsinsky Investigates Inovio Pharmaceuticals, Inc. for Securities Law Violations Ready to Announce with Confidence?

newsfilecorp.com
INO Levi & Korsinsky is investigating Inovio for securities law violations. The FDA did not accept their BLA for accelerated approval, leading to a significant stock price drop. The company is seeking to discuss accelerated approval with the FDA.

New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Inovio Pharmaceuticals, Inc. ("Inovio Pharmaceuticals, Inc.") (NASDAQ: INO) concerning potential violations of the federal securities laws.

The U.S. Food and Drug Administration ("FDA") announced on December 29, 2025, it had accepted Inovio's Biologics License Application ("BLA") for INO-3107, a treatment for recurrent respiratory papillomatosis, on a standard review timeline. Inovio filed its BLA under the accelerated approval pathway, but the FDA stated that the Company did not submit adequate information to justify eligibility for accelerated approval. Inovio also announced it does not currently plan to seek approval under the standard review timeline, and will request a meeting with the FDA to discuss how it may still pursue accelerated approval.

Following this news, Inovio's stock price fell over 24% on the same day.

If you suffered a loss on your Inovio Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212)363-7500

Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281118

Source: Levi & Korsinsky, LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.

ATTENTION BGIN Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

2026-01-21 2:44 PM EST

INO Investor Notice: Levi & Korsinsky Investigates Inovio Pharmaceuticals, Inc. for Securities Law Violations

2026-01-21 2:42 PM EST

Shareholders Alert: Investigation Into Wealthfront Corporation (WLTH) - Contact Levi & Korsinsky to Protect Your Rights

2026-01-21 1:10 PM EST

Dec 18, 2025

In 2025, more than 39,000 press releases distributed through Newsfile offer a clear lens into how public companies are communicating with the market. At this scale, individual announcements fade into the background, and what emerges instead are patterns . The language companies choose reveals how industries are evolving, where credibility is being built, and what investors are being asked to trust. Last year, this analysis focused on identifying the most common keywords by industry. This...

Economy, Business and Finance

Legal Service

Litigation and Regulation

Banking / Financial Services